<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="zh-CN">
		<id>http://120.24.161.253:5617/index.php?action=history&amp;feed=atom&amp;title=%E8%82%BF%E7%98%A4-%E8%8D%AF%E7%89%A9%E6%B2%BB%E7%96%97-%E7%A8%8B%E5%BA%8F%E6%80%A7%E6%AD%BB%E4%BA%A1%E8%9B%8B%E7%99%BD1%EF%BC%88PD-1%EF%BC%89%E5%92%8C%E7%BB%86%E8%83%9E%E6%AF%92%E6%80%A7T%E6%B7%8B%E5%B7%B4%E7%BB%86%E8%83%9E%E6%8A%97%E5%8E%9F4%EF%BC%88CTLA-4%EF%BC%89%E6%8A%91%E5%88%B6%E5%89%82%E5%B7%B2%E7%BB%8F%E5%B9%BF%E6%B3%9B%E7%94%A8%E4%BA%8E%E8%82%BF%E7%98%A4%E4%B8%B4%E5%BA%8A%E6%B2%BB%E7%96%97%EF%BC%8C%E5%88%BA%E6%BF%80%E6%80%A7%E6%A3%80%E6%9F%A5%E7%82%B9GITR</id>
		<title>肿瘤-药物治疗-程序性死亡蛋白1（PD-1）和细胞毒性T淋巴细胞抗原4（CTLA-4）抑制剂已经广泛用于肿瘤临床治疗，刺激性检查点GITR - 版本历史</title>
		<link rel="self" type="application/atom+xml" href="http://120.24.161.253:5617/index.php?action=history&amp;feed=atom&amp;title=%E8%82%BF%E7%98%A4-%E8%8D%AF%E7%89%A9%E6%B2%BB%E7%96%97-%E7%A8%8B%E5%BA%8F%E6%80%A7%E6%AD%BB%E4%BA%A1%E8%9B%8B%E7%99%BD1%EF%BC%88PD-1%EF%BC%89%E5%92%8C%E7%BB%86%E8%83%9E%E6%AF%92%E6%80%A7T%E6%B7%8B%E5%B7%B4%E7%BB%86%E8%83%9E%E6%8A%97%E5%8E%9F4%EF%BC%88CTLA-4%EF%BC%89%E6%8A%91%E5%88%B6%E5%89%82%E5%B7%B2%E7%BB%8F%E5%B9%BF%E6%B3%9B%E7%94%A8%E4%BA%8E%E8%82%BF%E7%98%A4%E4%B8%B4%E5%BA%8A%E6%B2%BB%E7%96%97%EF%BC%8C%E5%88%BA%E6%BF%80%E6%80%A7%E6%A3%80%E6%9F%A5%E7%82%B9GITR"/>
		<link rel="alternate" type="text/html" href="http://120.24.161.253:5617/index.php?title=%E8%82%BF%E7%98%A4-%E8%8D%AF%E7%89%A9%E6%B2%BB%E7%96%97-%E7%A8%8B%E5%BA%8F%E6%80%A7%E6%AD%BB%E4%BA%A1%E8%9B%8B%E7%99%BD1%EF%BC%88PD-1%EF%BC%89%E5%92%8C%E7%BB%86%E8%83%9E%E6%AF%92%E6%80%A7T%E6%B7%8B%E5%B7%B4%E7%BB%86%E8%83%9E%E6%8A%97%E5%8E%9F4%EF%BC%88CTLA-4%EF%BC%89%E6%8A%91%E5%88%B6%E5%89%82%E5%B7%B2%E7%BB%8F%E5%B9%BF%E6%B3%9B%E7%94%A8%E4%BA%8E%E8%82%BF%E7%98%A4%E4%B8%B4%E5%BA%8A%E6%B2%BB%E7%96%97%EF%BC%8C%E5%88%BA%E6%BF%80%E6%80%A7%E6%A3%80%E6%9F%A5%E7%82%B9GITR&amp;action=history"/>
		<updated>2026-04-27T17:36:42Z</updated>
		<subtitle>本wiki的该页面的版本历史</subtitle>
		<generator>MediaWiki 1.30.0</generator>

	<entry>
		<id>http://120.24.161.253:5617/index.php?title=%E8%82%BF%E7%98%A4-%E8%8D%AF%E7%89%A9%E6%B2%BB%E7%96%97-%E7%A8%8B%E5%BA%8F%E6%80%A7%E6%AD%BB%E4%BA%A1%E8%9B%8B%E7%99%BD1%EF%BC%88PD-1%EF%BC%89%E5%92%8C%E7%BB%86%E8%83%9E%E6%AF%92%E6%80%A7T%E6%B7%8B%E5%B7%B4%E7%BB%86%E8%83%9E%E6%8A%97%E5%8E%9F4%EF%BC%88CTLA-4%EF%BC%89%E6%8A%91%E5%88%B6%E5%89%82%E5%B7%B2%E7%BB%8F%E5%B9%BF%E6%B3%9B%E7%94%A8%E4%BA%8E%E8%82%BF%E7%98%A4%E4%B8%B4%E5%BA%8A%E6%B2%BB%E7%96%97%EF%BC%8C%E5%88%BA%E6%BF%80%E6%80%A7%E6%A3%80%E6%9F%A5%E7%82%B9GITR&amp;diff=1136447&amp;oldid=prev</id>
		<title>Admin：修改1</title>
		<link rel="alternate" type="text/html" href="http://120.24.161.253:5617/index.php?title=%E8%82%BF%E7%98%A4-%E8%8D%AF%E7%89%A9%E6%B2%BB%E7%96%97-%E7%A8%8B%E5%BA%8F%E6%80%A7%E6%AD%BB%E4%BA%A1%E8%9B%8B%E7%99%BD1%EF%BC%88PD-1%EF%BC%89%E5%92%8C%E7%BB%86%E8%83%9E%E6%AF%92%E6%80%A7T%E6%B7%8B%E5%B7%B4%E7%BB%86%E8%83%9E%E6%8A%97%E5%8E%9F4%EF%BC%88CTLA-4%EF%BC%89%E6%8A%91%E5%88%B6%E5%89%82%E5%B7%B2%E7%BB%8F%E5%B9%BF%E6%B3%9B%E7%94%A8%E4%BA%8E%E8%82%BF%E7%98%A4%E4%B8%B4%E5%BA%8A%E6%B2%BB%E7%96%97%EF%BC%8C%E5%88%BA%E6%BF%80%E6%80%A7%E6%A3%80%E6%9F%A5%E7%82%B9GITR&amp;diff=1136447&amp;oldid=prev"/>
				<updated>2024-07-06T14:00:00Z</updated>
		
		<summary type="html">&lt;p&gt;修改1&lt;/p&gt;
&lt;table class=&quot;diff diff-contentalign-left&quot; data-mw=&quot;interface&quot;&gt;
				&lt;tr style=&quot;vertical-align: top;&quot; lang=&quot;zh-CN&quot;&gt;
				&lt;td colspan=&quot;1&quot; style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;←上一版本&lt;/td&gt;
				&lt;td colspan=&quot;1&quot; style=&quot;background-color: white; color:black; text-align: center;&quot;&gt;2024年7月6日 (六) 14:00的版本&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; style=&quot;text-align: center;&quot; lang=&quot;zh-CN&quot;&gt;&lt;div class=&quot;mw-diff-empty&quot;&gt;（没有差异）&lt;/div&gt;
&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</summary>
		<author><name>Admin</name></author>	</entry>

	<entry>
		<id>http://120.24.161.253:5617/index.php?title=%E8%82%BF%E7%98%A4-%E8%8D%AF%E7%89%A9%E6%B2%BB%E7%96%97-%E7%A8%8B%E5%BA%8F%E6%80%A7%E6%AD%BB%E4%BA%A1%E8%9B%8B%E7%99%BD1%EF%BC%88PD-1%EF%BC%89%E5%92%8C%E7%BB%86%E8%83%9E%E6%AF%92%E6%80%A7T%E6%B7%8B%E5%B7%B4%E7%BB%86%E8%83%9E%E6%8A%97%E5%8E%9F4%EF%BC%88CTLA-4%EF%BC%89%E6%8A%91%E5%88%B6%E5%89%82%E5%B7%B2%E7%BB%8F%E5%B9%BF%E6%B3%9B%E7%94%A8%E4%BA%8E%E8%82%BF%E7%98%A4%E4%B8%B4%E5%BA%8A%E6%B2%BB%E7%96%97%EF%BC%8C%E5%88%BA%E6%BF%80%E6%80%A7%E6%A3%80%E6%9F%A5%E7%82%B9GITR&amp;diff=1136448&amp;oldid=prev</id>
		<title>KGadmin：导入1个版本</title>
		<link rel="alternate" type="text/html" href="http://120.24.161.253:5617/index.php?title=%E8%82%BF%E7%98%A4-%E8%8D%AF%E7%89%A9%E6%B2%BB%E7%96%97-%E7%A8%8B%E5%BA%8F%E6%80%A7%E6%AD%BB%E4%BA%A1%E8%9B%8B%E7%99%BD1%EF%BC%88PD-1%EF%BC%89%E5%92%8C%E7%BB%86%E8%83%9E%E6%AF%92%E6%80%A7T%E6%B7%8B%E5%B7%B4%E7%BB%86%E8%83%9E%E6%8A%97%E5%8E%9F4%EF%BC%88CTLA-4%EF%BC%89%E6%8A%91%E5%88%B6%E5%89%82%E5%B7%B2%E7%BB%8F%E5%B9%BF%E6%B3%9B%E7%94%A8%E4%BA%8E%E8%82%BF%E7%98%A4%E4%B8%B4%E5%BA%8A%E6%B2%BB%E7%96%97%EF%BC%8C%E5%88%BA%E6%BF%80%E6%80%A7%E6%A3%80%E6%9F%A5%E7%82%B9GITR&amp;diff=1136448&amp;oldid=prev"/>
				<updated>2024-07-06T08:58:04Z</updated>
		
		<summary type="html">&lt;p&gt;导入1个版本&lt;/p&gt;
&lt;p&gt;&lt;b&gt;新页面&lt;/b&gt;&lt;/p&gt;&lt;div&gt;主实体：[[肿瘤]]，关系：[[药物治疗]] ，尾实体：[[程序性死亡蛋白1（PD-1）和细胞毒性T淋巴细胞抗原4（CTLA-4）抑制剂已经广泛用于肿瘤临床治疗，刺激性检查点GITR]]&lt;br /&gt;
&lt;br /&gt;
实体ID:''11088390''&lt;br /&gt;
==关系介绍==&lt;br /&gt;
待补充&lt;br /&gt;
&lt;br /&gt;
==来源==&lt;br /&gt;
===免疫检查点激动剂治疗实体瘤的研究进展（中华医学会文献）===&lt;br /&gt;
摘要 免疫检查点由抑制性和刺激性分子组成，抑制性检查点程序性死亡蛋白1（PD-1）和细胞毒性T淋巴细胞抗原4（CTLA-4）抑制剂已经广泛用于[[肿瘤]]临床治疗，刺激性检查点GITR、OX40、4-1BB、ICOS、CD40和STING激动剂正在进行临床试验。&lt;/div&gt;</summary>
		<author><name>KGadmin</name></author>	</entry>

	</feed>